• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Renovaro Inc. (Amendment)

    2/22/24 4:17:11 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RENB alert in real time by email
    SC 13G/A 1 ea0200498-13ga2abildga_reno.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Renovaro Inc.
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

    29350E104
    (CUSIP Number)

     

    February 13, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Page 1 of 10 Pages)

     

     

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 2 of 10

     

    1.

    Name of Reporting Persons

     

    Paseco ApS

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐

    (b) ☒

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    Denmark

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,157,447

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,157,447

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,157,447

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    7.6%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    FI

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 3 of 10

     

    1.

    Name of Reporting Persons

     

    Ole Abildgaard

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐

    (b) ☒

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    Denmark

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting Person
    With

    5.

    Sole Voting Power

     

    5,000

    6.

    Shared Voting Power

     

    11,157,447

    7.

    Sole Dispositive Power

     

    5,000

    8.

    Shared Dispositive Power

     

    11,157,447

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,162,447

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    7.6%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CP

      

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 4 of 10

     

    Item 1. (a) Name of Issuer:
         
        Renovaro Inc.
       

     

      (b) Address of Issuer’s Principal Executive Offices:
         
       

    2080 Century Park East, Suite 906

    Los Angeles, CA 90067

    United States of America

         
    Item 2. (a) Name of Person Filing:
         
        This Schedule 13G/A is filed by the following (the “Reporting Persons”): (1) Paseco ApS (“Paseco”) and (2) Ole Abildgaard (the “CP”). Paseco is a private investment vehicle. The CP is the Chief Executive Officer and sole shareholder of Paseco. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
         
      (b) Address of Principal Business Office, or if None, Residence:
         
       

    Paseco ApS

    Vedbaek Strandvej 506

    2950 Vedbaek

    Denmark

    Ole Abildgaard

    Vedbaek Strandvej 506

    2950 Vedbaek

    Denmark

     

      (c) Citizenship:
         
       

    Paseco ApS – Denmark

    Ole Abildgaard – Denmark

         
      (d) Title of Class of Securities:
         
        Common Stock, par value $0.0001 per share
         
      (e) CUSIP Number:
         
        29350E104

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 5 of 10

     

    Item 3.   If this statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
         
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☒

    A non-U.S. institution in accordance with s.240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with s.240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment Company.

     

      (k) ☐

    Group, in accordance with s.240.13d-1(b)(1)(ii)(K).

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 6 of 10

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:(1)
         
       

    Paseco ApS – 11,157,447

    Ole Abildgaard – 11,162,447

       

     

      (b) Percent of class:(2)
         
       

    Paseco ApS – 7.6%

    Ole Abildgaard – 7.6%

         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote
         

     

    Paseco ApS – 0

    Ole Abildgaard – 5,000

           
        (ii) Shared power to vote or to direct the vote
         

     

    Paseco ApS – 11,157,447

    Ole Abildgaard – 11,157,447

           
        (iii) Sole power to dispose or to direct the disposition of
         

     

    Paseco ApS – 0

    Ole Abildgaard – 5,000

           
        (iv) Shared power to dispose or to direct the disposition of
         

     

    Paseco ApS – 11,157,447

    Ole Abildgaard – 11,157,447

     

    1.Mr. Abildgaard is the Chief Executive Officer, and sole shareholder of Paseco ApS (“Paseco”). Thus, Mr. Abildgaard and Paseco have shared voting and investment power over the shares of Common Stock of the Issuer directly held by Paseco. Paseco’s holdings include (i) 7,898,482 shares of Common Stock, including 3,436,190 shares of Common Stock that were issued to Paseco upon the automatic conversion of 343,619 shares of Series A Preferred Stock on February 13, 2024 pursuant to their terms in accordance with the closing of the Issuer’s acquisition of FEDi Cube Intl. Ltd. pursuant to that certain Stock Purchase Agreement, dated September 28, 2023, by and among the Issuer, GEDi Cube Intl., Ltd., the other sellers party thereto, and Yalla Yalla Ltd., in its capacity as the representative of the sellers, and (ii) warrants exercisable into 3,258,965 shares of Common Stock.

     

    2.This percentage is calculated based on 143,668,372 shares of Common Stock issued and outstanding as of February 14, 2024 as reported on the cover of the Issuer’s Quarterly Report on Form 10-Q for the period ended December 31, 2023, which was filed with the Securities and Exchange Commission on February 14, 2024, plus 3,258,965 shares of Common Stock issuable upon exercise of the warrants to purchase Common Stock held directly by Paseco.

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 7 of 10

     

    Item 5. Ownership of 5 Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
     
      N/A

     

     
    Item 6. Ownership of More Than 5 Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A

     

     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 8 of 10

     

    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A

     

     
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A

     

    Item 10. Certification.
     
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
       
      By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to investment companies in Denmark is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 9 of 10

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 22, 2024  
    (Date)  

     

    Paseco ApS*  
         
    By: Ole Abildgaard  
         
    By: /s/ Ole Abildgaard  
      (Signature)  
         
      Ole Abildgaard, Chief Executive Officer  
      (Name/Title)  
         
    Ole Abildgaard*  
         
    By: /s/ Ole Abildgaard  
      (Signature)  
         
      Ole Abildgaard  
      (Name/Title)  

     

    *This Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

     

    Percent

     

     

     

    SCHEDULE 13G/A

     

    CUSIP NO. 29350E104 Page 10 of 10

     

    LIST OF EXHIBITS

     

    Exhibit No.   Description
    99.1   Joint Filing Agreement

     

     

     

     

    Get the next $RENB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RENB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RENB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      3/12/25 8:12:50 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:33:34 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:29:46 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Leadership Updates

    Live Leadership Updates

    See more
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin

      2/26/25 1:25:00 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Appoints Nathen Fuentes as Chief Financial Officer

      Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial l

      1/7/25 9:15:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

      LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-performance computing ("HPC") built on the latest platform to accelerate biomarker discovery and next-generation diagnostics. David Weinstein, CEO of Renovaro, stated, "By utilizing Nebul'

      4/22/25 9:20:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Provides Update to Definitive Agreement with Predictive Oncology

      LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ:POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. ("POI") dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025

      4/4/25 9:40:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RENB
    SEC Filings

    See more
    • Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/18/25 5:00:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/10/25 4:55:50 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RENOVARO INC. (0001527728) (Filer)

      2/28/25 4:05:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      11/6/24 5:45:52 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      10/24/24 8:57:01 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      6/24/24 7:56:04 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care